IP Library Granted Patent US 7,869,959
Granted Patent B2
US 7,869,959 · App. 11/346,927 · Granted Jan 11, 2011

Optimized probe selection method

Assignee: Roche Nimblegen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,869,959
App. No.
11/346,927
Granted
Jan 11, 2011
Kind
B2
Abstract

The present invention provides methods for optimizing oligonucleotide hybridization probes for use in basic and clinical research. Specifically, the invention involves hybridizing serially diluted genomic sample to the oligonucleotide probes on the array, such that a signal intensity is produced for each of the probes; computationally identifying optimized probes which exhibit signal intensities that correspond to the serial dilutions of genomic sample and are reproducibly strong relative to non-optimized probes.

Claims (12)

1. A method for optimizing oligonucleotide probes for use in a hybridization-based assay, the method comprising the steps of:

a) providing a plurality of oligonucleotide probes on a hybridization array;

b) providing serial dilutions of a genomic sample, wherein the genomic sample is labeled;

c) hybridizing the labeled and serially diluted genomic sample to the probes on the array, such that a signal intensity is produced for each of the probes, wherein the hybridization step is performed at least one time;

d) computationally generating weighted regression data from the signal intensity produced for each of the probes; and

e) identifying optimized probes from the plurality of oligonucleotide probes on the hybridization array for use in the assay using a probe selection algorithm reliant upon the weighted regression data, the optimized probes exhibiting signal intensities proportional to the serial dilutions of the genomic sample and having maximal brightness at each serial dilution.

2. The method of claim 1 wherein the oligonucleotide probes are DNA or RNA.

3. The method of claim 1 wherein the hybridization-based assay is selected from the group consisting of a microarray-based assay, bead-based assay, genotyping assay, and RNAi assay.

4. The method of claim 1 , wherein said probe selection algorithm for identifying optimized probes is a rank selection algorithm.

5. The method of claim 4 , wherein said rank selection algorithm for identifying optimized probes comprises calculating a score for each probe utilizing criteria comprising weighted slope, weighted correlation coefficient, intensity and positional weight.

6. The method of claim 1 , wherein said hybridization-based assay is a microarray-based assay.

7. The method of claim 6 , wherein said microarray is synthesized by maskless array synthesis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2014
From: RICHMOND, TODD; NORTON, JASON; NUWAYSIR, EMILE F.; GREEN, ROLAND; NUWAYSIR, KATE
To: NIMBLEGEN SYSTEMS, INC.
Reel/Frame 033350/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2014
From: ROCHE NIMBLEGEN, INC.
To: VENTANA MEDICAL SYSTEMS, INC.
Reel/Frame 033352/0418 →
CHANGE OF NAME Recorded Jul 21, 2014
From: NIMBLEGEN SYSTEMS, INC.
To: ROCHE NIMBLEGEN, INC.
Reel/Frame 033371/0492 →
Continuity (2)
Provisional Application 6065026500 · Feb 4, 2005
Related Publication 20060177858A1 · Aug 10, 2006